Last reviewed · How we verify

BiondVax Pharmaceuticals ltd. — Portfolio Competitive Intelligence Brief

BiondVax Pharmaceuticals ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 3 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
M-001 M-001 phase 3 Recombinant protein vaccine Conserved influenza virus epitopes Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  2. D'Or Institute for Research and Education · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Henogen · 1 shared drug class
  5. Henry M. Jackson Foundation for the Advancement of Military Medicine · 1 shared drug class
  6. Institut National de la Santé Et de la Recherche Médicale, France · 1 shared drug class
  7. National Vaccine and Serum Institute, China · 1 shared drug class
  8. ANRS, Emerging Infectious Diseases · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BiondVax Pharmaceuticals ltd.:

Cite this brief

Drug Landscape (2026). BiondVax Pharmaceuticals ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biondvax-pharmaceuticals-ltd. Accessed 2026-05-16.

Related